Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Raynaud's Phenomenon Secondary to Connective Tissue Disease

Interventions

DRUG

Vascana (0.9% nitroglycerin cream)

Study drug administered topically

DRUG

Vehicle Cream (placebo)

Vehicle administered topically

Trial Locations (1)

Multiple investigational sites, Multiple Locations